What makes IGF-1 LR3 different from natural IGF-1?

Its amino-acid substitution and N-terminal extension greatly lower binding to IGF-binding proteins, giving it a much longer half-life and more sustained anabolic activity than native IGF-1.

Why combine IGF-1 LR3 with BPC-157?

IGF-1 LR3 drives anabolic growth and protein synthesis while BPC-157 supports angiogenesis and tissue repair, so the blend is studied for both muscle gain and injury recovery.

Is this blend safe and approved?

No. It is sold as a research chemical without FDA approval, and the potent growth-promoting activity of IGF-1 LR3 raises safety concerns that warrant caution.

← All peptides

Healing & Recovery

Research Chemical

IGF-1 LR3 / BPC-157 Blend

Also known as: IGF-1 LR3 + BPC-157 Blend

A research blend combining the long-acting growth factor IGF-1 LR3 with the cytoprotective peptide BPC-157 to support anabolic growth and tissue repair. It is studied for muscle growth, recovery, and injury healing.

Mechanism of Action

IGF-1 LR3 is a modified analog of insulin-like growth factor 1 with an Arg substitution at position 3 and a 13-amino-acid N-terminal extension, which markedly reduces its binding to IGF-binding proteins and extends its half-life. It activates the IGF-1 receptor and downstream PI3K/Akt/mTOR and MAPK pathways to drive protein synthesis, cell proliferation, and hypertrophy. BPC-157 complements this by promoting angiogenesis through VEGFR2 signaling, activating the nitric oxide system, and enhancing fibroblast migration and growth-factor receptor expression for tendon and soft-tissue repair. The blend pairs potent anabolic signaling with cytoprotective, angiogenic repair.

Half-life: IGF-1 LR3 is extended to roughly 20-30 hours due to reduced binding-protein affinity, while BPC-157 is short-lived (minutes to a few hours).
Administration Routes: subcutaneous
Research Status: Research Chemical